Abstracts tagged "Osteoarthritis"

Abstract Number: 1470 • ACR Convergence 2020
Machine Learning-Based Prediction of Knee Replacement in Persons with and Without Radiographic Osteoarthritis Using Clinical and Imaging Features of Osteoarthritis: The Multicenter Osteoarthritis Study
S. Reza Jafarzadeh¹, David Felson¹, Michael Nevitt², James Torner³, Cora Lewis⁴, Frank Roemer⁵, Ali Guermazi¹ and Tuhina Neogi¹, ¹Boston University School of Medicine, Boston, MA, ²University of California, San Francisco, San Francisco, CA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Prior studies of predictors of knee replacement (KR) have often included only a limited set of risk factors, been conducted primarily in knees with…
Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter¹, Tuhina Neogi², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi², Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ²Boston University School of Medicine, Boston, MA, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1657 • ACR Convergence 2020
Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?
Lauren King¹, Esther Waugh¹, Allyson Jones², Deborah Marshall³ and Gillian Hawker⁴, ¹University of Toronto, Toronto, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with knee osteoarthritis (OA) are increasingly living with multiple comorbid conditions. The presence of comorbidities has been associated with having worse OA symptoms…
Abstract Number: 0150 • ACR Convergence 2020
The Preparation Experience for Total Knee Arthroplasty of Patients with Osteoarthritis: A Cross-Sectional Survey
Aretina Leung¹, Geyanne Lui², Susan Goodman³, Lisa Mandl⁴, Peter Sculco⁵, Mark Figgie³ and Iris Navarro-Millan¹, ¹Weill Cornell Medicine, New York, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: We previously identified several barriers and facilitators of exercise before total knee arthroplasty (TKA) in a small qualitative study, as well as the existence…
Abstract Number: 0700 • ACR Convergence 2020
Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Mandar Dave¹, Abul Islam², Akshat Parekh³, Jay Patel⁴, Arushi Chawla⁵ and Ashok Amin⁶, ¹Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, ²Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh, ³Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, ⁴Northeast Ohio Medical University, Rootstown, OH, ⁵Gujarat Forensic Science University, Gujarat, India, ⁶Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Human OA-affected cartilage does not show the cardinal signs of inflammation (redness and swelling with heat and pain—rubor et tumor cum calore et dolor) because…
Abstract Number: 1100 • ACR Convergence 2020
The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity
Fernando Bomfim¹, Shannon Chen², Stephen Zak³, Taylor Jazrawi², Vivienne Qie³, Benjamin Plotz² and Jonathan Samuels⁴, ¹New York University, Department of Medicine, Division of Rheumatology, Millburn, NJ, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY, ⁴NYU Langone, Rye Brook, NY
Background/Purpose: Hand osteoarthritis (HOA) data is often obtained from large knee OA cohorts. Targeted HOA cohorts in Europe have shed light on this disease, but…
Abstract Number: 1116 • ACR Convergence 2020
Magnetic Resonance Imaging Structural Changes Correlated with Knee Extension: Data from the Osteoarthritis Initiative
T Mark Campbell¹, Guy Trudel² and Dennis McGonagle³, ¹Elisabeth Bruyère Hospital, Ottawa, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Knee OA is often accompanied by loss of passive extension, termed a flexion contracture (FC), resulting in worse clinical outcomes. To our knowledge, MRI-based…
Abstract Number: 1482 • ACR Convergence 2020
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁷ and Kenneth Verburg⁸, ¹Hospital for Special Surgery, Hackensack, NJ, ²Tufts Medical Center, Boston, MA, ³Université Claude Bernard Lyon 1, Pierre Benite, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1658 • ACR Convergence 2020
Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis
Marieke Loef¹, Rob van der Geest¹, Hildo Lamb¹, Renée de Mutsert¹, Frits Rosendaal¹ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Obesity-related metabolic dysregulation may lead to atherosclerotic vascular changes. It has been hypothesized that a compromised blood flow may cause detrimental changes to the…
Abstract Number: 0153 • ACR Convergence 2020
Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis
Anna Falls¹, Peta-Gay Ricketts¹, John Elliott¹ and Kim Jordan¹, ¹OhioHealth Riverside Methodist Hospital, Columbus, OH
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) cause functional impairments that impact daily life activities, including automobile driving. Radiographic presence of OA on knee and…
Abstract Number: 0701 • ACR Convergence 2020
miRNome Sequencing Identifies a Unique Profile of Circulating MicroRNAs in Early Knee Osteoarthritis
S. Amanda Ali¹, Rajiv Gandhi², Pratibha Potla², Sareh Keshavarzi², Osvaldo Espin-Garcia², Konstantin Shestopaloff², Chiara Pastrello³, Dylan Bethune-Waddell², Starlee Lively², Anthony Perruccio⁴, Raj Rampersaud², Christian Veillette², Jason Rockel², Igor Jurisica², Tom Appleton⁵ and Mohit Kapoor⁶, ¹Henry Ford Health System, Detroit, MI, ²Krembil RI, Toronto, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, ⁵The University of Western Ontario, LONDON, ON, Canada, ⁶Krembil RI, Toronto, ON, Canada
Background/Purpose: MicroRNAs have been shown to contribute to osteoarthritis (OA) pathophysiology, yet little is known about the circulating miRNome in OA. The circulating miRNome (e.g.…
Abstract Number: 1101 • ACR Convergence 2020
Effect of Transcutaneous Vagal Nerve Stimulation in Erosive Hand Osteoarthritis: Results from an Open-label Non-randomized Pilot Trial
Alice Courties¹, Camille Deprouw², Emmanuel Maheu³, Eric Gibert⁴, Jacques-Eric Gottenberg⁵, Julien Champey⁶, Béatrice Banneville⁷, Camille Chesnel⁸, Gerard Amarenco⁸, Alexandra Rousseau⁹, Francis Berenbaum¹ and Jeremie Sellam¹, ¹AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²1. AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012, France, Paris, France, ³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012, Paris, France, ⁴Cabinet de Rhumatologie, 94200 Ivry sur Seine, Paris, France, ⁵Service de Rhumatologie, Centre national de référence pour les maladies auto-immunes systémiques, Hôpital universitaire de Strasbourg, Université de Strasbourg, Strasbourg,, Strasbourg, France, ⁶AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012,, paris, France, ⁷AP-HP, Hôpital Pitié-Salpêtrière, Service de Rhumatologie, Paris, 75013, Paris, France, ⁸Sorbonne Université, GRC 001, GREEN Groupe de Recherche Clinique en Neuro-Urologie, AP-HP, Hôpital Tenon, F-75020 Paris,, Paris, France, ⁹AP-HP, Hôpital Saint-Antoine, Unité de Recherche Clinique de l'Est Parisien (URC-Est), Paris, 75012,, Paris, France
Background/Purpose: Beyond classical effect on vegetative functions, the activation of the vagus nerve inhibits inflammation and reduces the pain signal. Vagus nerve stimulation (VNS) can…
Abstract Number: 1117 • ACR Convergence 2020
Prediction Model for Progression to Different Find-Grained MRI-Based Osteoarthritis Severity States: The Vancouver Longitudinal Study of Early Knee Osteoarthritis (VALSEKO)
Jolanda Cibere¹, Ali Guermazi², Savvas Nicolaou³, Jacek Kopec⁴, John Esdaile⁵, Hubert Wong⁶, Joel Singer⁶, Anona Thorne⁶ and Eric Sayre⁷, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada, Vancouver, BC, Canada, ⁶University of British Columbia, Vancouver, Canada, ⁷Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: To develop a novel, fine-grained MRI osteoarthritis (OA) severity score, based on cartilage, osteophytes and meniscus (OA-COM) scores and to predict the progression to…
Abstract Number: 1483 • ACR Convergence 2020
A Randomised Controlled Trial Evaluating the Efficacy of Internet-based Exercises Aimed at Treating Knee Osteoarthritis (iBEAT-OA)
Sameer Gohir¹, Abhishek Abhishek², Anthony Kelly² and Ana M Valdes³, ¹NIHR Nottingham Biomedical Research Centre, GRAYS ESSEX, England, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is the commonest cause of pain and disability in the general population and is usually managed by family doctors and physiotherapists. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].